Approaching Resistance to Targeted Inhibition of PI3K in Breast Cancer

doi 10.21236/ada555900
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Defense Technical Information Center

Related search

Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer

Cancer Discovery
Oncology
2016English

Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells

Cancer Cell
Cancer ResearchOncologyCell Biology
2012English

mTORC1 Inhibition Is Required for Sensitivity to PI3K P110 Inhibitors in PIK3CA-Mutant Breast Cancer

Science Translational Medicine
Medicine
2013English

Interleukin-6 Mediates Resistance to PI3K-pathway–targeted Therapy in Lymphoma

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

Vertical Inhibition of the PI3K/Akt/mTOR Pathway Is Synergistic in Breast Cancer

Oncogenesis
Cancer ResearchMolecular Biology
2017English

Targeted Therapy for Advanced Prostate Cancer: Inhibition of the PI3K/Akt/mTOR Pathway

Current Cancer Drug Targets
Cancer ResearchDrug DiscoveryOncologyPharmacology
2009English

Targeted Lapatinib Anti-Her2/ErbB2 Therapy Resistance in Breast Cancer: Opportunities to Overcome a Difficult Problem

2020English

CXCR4-targeted Therapy in Breast Cancer

The Lancet Oncology
Oncology
2018English

Dual Inhibition of PI3K and mTOR Mitigates Compensatory AKT Activation and Improves Tamoxifen Response in Breast Cancer

Molecular Cancer Research
Cancer ResearchOncologyMolecular Biology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy